Core Viewpoint - 罗欣药业 is a key player in the pharmaceutical industry, focusing on research, production, and sales, with a notable presence in various market segments, including e-commerce and innovative medical concepts [1] Group 1: Business Performance - In Q3 2025, 罗欣药业 achieved a revenue of 1.723 billion yuan, ranking 38th among 110 companies in the industry, while the top company, 华东医药, reported a revenue of 32.664 billion yuan [2] - The net profit for the same period was 33.5591 million yuan, placing the company at 68th in the industry, with the leading company, 恒瑞医药, reporting a net profit of 5.76 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, 罗欣药业's debt-to-asset ratio was 61.65%, an increase from 55.94% year-on-year, and significantly higher than the industry average of 35.26% [3] - The gross profit margin for the company was 51.77%, up from 42.81% year-on-year, but still below the industry average of 57.17% [3] Group 3: Executive Compensation - The chairman, 刘振腾, received a salary of 1.8672 million yuan in 2024, a slight decrease from 1.8796 million yuan in 2023 [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 3.53% to 38,300, while the average number of circulating A-shares held per shareholder increased by 3.66% to 28,400 [5] - Among the top ten circulating shareholders, 香港中央结算有限公司 ranked fifth, holding 30.3383 million shares, an increase of 15.1142 million shares from the previous period [5]

证券代码：002793 证券简称：罗欣药业 公告编号：2025-099 罗欣药业集团股份有限公司 关于为控股子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 罗欣药业集团股份有限公司（以下简称"公司"）及控股子公司对外担保总 额超过最近一期经审计净资产 100%；公司及控股子公司担保金额超过上市公司 最近一期经审计净资产 50%，提请投资者充分关注担保风险。 一、担保情况概述 为满足日常生产经营及业务拓展资金需要，保证生产经营持续发展和业务顺 利开展，公司拟为其控股子公司山东罗欣药业集团股份有限公司（以下简称"山 东罗欣"）人民币 11,000 万元银行授信额度提供担保。公司于 2025 年 1 月 14 日召开第五届董事会第二十一次会议及第五届监事会第十八次会议，分别以 6 票同意、0 票反对、0 票弃权及 4 票同意、0 票反对、0 票弃权的表决结果，审议 通过了《关于为控股子公司提供担保的议案》。具体内容详见公司于 2025 年 1 月 15 日刊登于巨潮资讯网（http://www.cninfo.com.cn）的《关 ...

Core Viewpoint - The stock price of Luoxin Pharmaceutical has experienced fluctuations, with a year-to-date increase of 34.82% but a recent decline of 6.19% over the past five trading days [2]. Company Performance - As of October 30, Luoxin Pharmaceutical's stock price was 5.15 CNY per share, with a market capitalization of 5.601 billion CNY [1]. - The company reported a revenue of 1.723 billion CNY for the period from January to September 2025, representing a year-on-year decrease of 8.37%. However, the net profit attributable to shareholders increased by 108.64% to 22.93 million CNY [2]. Shareholder Information - The number of shareholders increased by 26.23% to 48,300 as of October 20, 2025, while the average circulating shares per person decreased by 20.78% to 22,481 shares [2]. - Luoxin Pharmaceutical has distributed a total of 330 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3]. Stock Trading Activity - The stock has seen a net inflow of 462,700 CNY from main funds, with large orders accounting for 12.03% of total buying and 9.77% of total selling [1]. - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent occurrence on July 31 [2]. Business Overview - Luoxin Pharmaceutical, established in May 1998 and listed in April 2016, is primarily engaged in the research, production, and sales of pharmaceutical products. Its main revenue sources include digestive system products (49.54%), antibiotics (22.12%), and other categories [2].

Core Insights - 罗欣药业 reported its Q3 2025 financial results, highlighting significant institutional investor interest with a total of 4.35 billion shares held, representing 39.96% of the company's total equity [1] Institutional Holdings - As of October 27, 2025, seven institutional investors disclosed their holdings in 罗欣药业, with a combined ownership increase of 0.80 percentage points from the previous quarter [1] - Major institutional investors include 山东罗欣控股有限公司, 上海中珏私募基金管理有限公司, ALLY BRIDGE FLAGSHIP LX (HK) LIMITED, and others [1] Public Fund Activity - In this reporting period, 22 public funds were disclosed, including 富国稳健增长混合A, 华宝创新优选混合, and others, indicating continued interest from public investment vehicles [1] Foreign Investment - One foreign fund, 香港中央结算有限公司, increased its holdings by 1.39% compared to the previous period, reflecting a positive sentiment from foreign investors [1]

Summary of Key Points Core Viewpoint - 罗欣药业's recent financial disclosures indicate a mixed performance in non-recurring gains and losses, with significant fluctuations over the past three years, highlighting the company's reliance on non-operational income sources [1][2]. Group 1: Financial Performance - As of October 27, 2025, 罗欣药业's stock closed at 5.31 yuan, down 0.75%, with a trading volume of 254,700 shares and a turnover of 136 million yuan [1]. - The net non-recurring gains and losses for 罗欣药业 from 2022 to the first nine months of 2025 were reported as 215,423,150.70 yuan, -22,285,473.56 yuan, -197,375,374.58 yuan, and 18,008,575.68 yuan respectively [1]. - The significant non-recurring gain in 2022 was primarily due to non-current asset disposal, amounting to 136,264,318.65 yuan, while a loss of 213,130,913.80 yuan was recorded in 2024 due to fair value changes related to the disposal of 上药罗欣 [1]. Group 2: Fund Utilization - 罗欣药业's previous fundraising efforts totaled 663,566.00 million yuan, fully utilized for acquiring a 99.65476% stake in 山东罗欣药业 [2][3]. - The asset performance post-acquisition showed a net profit of 56,450.69 million yuan in 2019, but fell short of commitments in 2020 and 2021, leading to the cancellation of 371,334,114 shares as compensation [2]. - The total assets of 罗欣药业 decreased from 721,226.54 million yuan at the end of 2019 to 497,240.24 million yuan by the end of 2024 [2].

Core Insights - The company reported a revenue of 646,173,009.72 yuan for the third quarter of 2025, representing a year-on-year growth of 3.94% [1] - The net profit attributable to shareholders of the listed company was 5,231,766.19 yuan, showing a significant year-on-year increase of 102.96% [1]

罗欣药业集团股份有限公司 章 程 | 第一节 | 股东的一般规定 | 12 | | --- | --- | --- | | 第二节 | 控股股东和实际控制人 | 16 | | 第三节 | 股东会的一般规定 | 17 | | 第四节 | 股东会的召集 | 21 | | 第五节 | 股东会的提案和通知 | 22 | | 第六节 | 股东会的召开 | 24 | | 第七节 | 股东会的表决和决议 | 27 | | 第一节 | 董事的一般规定 | 32 | | 第二节 | 董 事 会 | 36 | | 第三节 | 独立董事 | 40 | | 第四节 | 董事会专门委员会 | 42 | | 第一节 | 财务会计制度 | 46 | | 第二节 | 内部审计 | 51 | | 第三节 | 会计师事务所的聘任 | 52 | | 第一节 | 合并、分立、增资和减资 | 54 | | 第二节 | 公司解散和清算 | 56 | 第一章 总 则 第一条 为维护公司、股东、职工和债权人的合法权益，规范公司的组织和 行为，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《中国 ...

罗欣药业集团股份有限公司 董事会议事规则 第一章 总则 第一条 为规范罗欣药业集团股份有限公司（以下简称"公司"或"本公司"） 董事会及其成员的行为，保障董事会高效运作和科学决策，根据《中华人民共和 国公司法》《中华人民共和国证券法》《深圳证券交易所股票上市规则》《深圳证 券交易所上市公司自律监管指引第 1 号—主板上市公司规范运作》及其他相关法 律、行政法规、部门规章、规范性文件和《罗欣药业集团股份有限公司章程》（以 下简称"《公司章程》"）的有关规定，特制定本规则。 第二章 董事 第二条 公司董事为自然人，有下列情形之一的，不得担任公司的董事： （一）无民事行为能力或者限制民事行为能力； （二）因贪污、贿赂、侵占财产、挪用财产或者破坏社会主义市场经济秩序， 被判处刑罚，或者因犯罪被剥夺政治权利，执行期满未逾 5 年，被宣告缓刑的， 自缓刑考验期满之日起未逾 2 年； （三）担任破产清算的公司、企业的董事或者厂长、总经理，对该公司、企 业的破产负有个人责任的，自该公司、企业破产清算完结之日起未逾 3 年； （九）法律、行政法规或部门规章规定的其他内容。 董事候选人应在知悉或理应知悉其被推举为董事候选人的第一 ...

章程修改条款对比表 | 序号 | 修改前内容 | 修改后内容 | | --- | --- | --- | | | 第一百一十二条 董事会由 6 名董 | 第一百一十二条 董事会由 7 名董事 | | | 事组成，其中独立董事 名。职工代表 3 | 组成，其中独立董事 名。职工代表董 3 | | 1 | 董事由职工代表大会、职工大会或其他 | 事 1 名，由职工代表大会、职工大会或 | | | 形式民主选举产生；其他董事由股东会 | 其他形式民主选举产生；其他董事由股 | | | 选举产生。 | 东会选举产生。 | | | 第一百三十八条 审计委员会成员 | 第一百三十八条 审计委员会成员 为 3 名，为不在公司担任高级管理人员 | | | 为 名，为不在公司担任高级管理人员 3 | | | 2 | | 的董事，其中独立董事 名，非独立董 2 | | | 的董事，其中独立董事 名，由独立董 2 | 事 名，由独立董事中会计专业人士担 | | | 事中会计专业人士担任召集人。 | 1 | | | | 任召集人。 | 罗欣药业集团股份有限公司 ...

一、前次募集资金情况 2019 年 5 月 31 日，公司第三届董事会第九次会议审议通过了《关于本次重大资产置换 及发行股份购买资产暨关联交易的议案》，2019 年 6 月 18 日，公司 2019 年度第一次临时 股东大会审议通过上述议案。根据上述议案，公司以置出资产作为对价与山东罗欣药业集团 股份有限公司（以下简称山东罗欣）股东合计持有的 99.65476%股权中的等值部分进行置换； 公司以非公开发行的股份购买重大资产置换后山东罗欣股东持有的剩余股权。此次重大资产 重组包括重大资产置换及发行股份购买资产，具体方案为： (一) 重大资产置换 此次重大资产置换的置出资产为截至 2018 年 12 月 31 日公司拥有的除保留资产外的全 部资产、业务及负债，置入资产为交易对方持有的山东罗欣的 99.65476%的股权。公司以置 出资产与交易对方合计持有的山东罗欣的 99.65476%股权中等值部分进行置换。 置出资产以坤元资产评估有限公司 2019 年 5 月 28 日出具的《评估报告》所确定的置出 资产截至 2018 年 12 月 31 日的评估价值 90,324.75 万元作为定价依据，经交易各方协商确 定 ...